Bidders for Sanofi’s consumer healthcare unit are revising their offers in part to address concerns around potential ...

Among the large drugmakers, Eli Lilly, AstraZeneca, Pfizer, Sanofi and Bayer are worth retaining in one’s portfolio.

As Sanofi continues to clean out its medicine chest, Italy’s Recordati is getting in on the action. | Recordati is floating ...

Sanofi has received two separate bids for its consumer health unit, which could be valued at 15 billion euros ($16.74 billion ...

Bank of America Securities analyst Graham Parry maintained a Buy rating on Sanofi (SNYNF – Research Report) today and set a price target ...

Recordati has reached an agreement with Sanofi for acquiring the worldwide rights to Enjaymo, the only approved treatment ...

Sanofi plans to spin off its consumer healthcare division, which could be valued at over $16.8 billion. Private equity firms ...

J.P. Morgan analyst Richard Vosser maintained a Hold rating on Sanofi (SNYNF – Research Report) today and set a price target of €100.00.

Sanofi has asked bidders to revise their proposals for its consumer health unit, people with knowledge of the matter said, as ...

The company entered the OTC business in 2007 and it has grown to have established brands such as Manforce, HealthOK, Prega ...

Sanofi’s Dupixent has been cleared for a chronic lung disorder in the US, in another milestone for the blockbuster drug after ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.